{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:37:40Z","timestamp":1791221860206,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40292-021-00439-9","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T16:12:44Z","timestamp":1614355964000},"page":"129-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update"],"prefix":"10.1007","volume":"28","author":[{"given":"Ashwin Kumar","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-8791","authenticated-orcid":false,"given":"Monisha","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"439_CR1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med."},{"issue":"4","key":"439_CR2","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.","journal-title":"Lancet Respir Med."},{"key":"439_CR3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"issue":"2","key":"439_CR4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/jcm9020575","volume":"9","author":"SQ Deng","year":"2020","unstructured":"Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575.","journal-title":"J Clin Med."},{"issue":"13","key":"439_CR5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for disease control and prevention. JAMA. 2020;323(13):1239\u201342.","journal-title":"JAMA"},{"issue":"18","key":"439_CR6","first-page":"1775","volume":"323","author":"G Onder","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775\u20136.","journal-title":"JAMA"},{"key":"439_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002666","author":"C Mancusi","year":"2020","unstructured":"Mancusi C, Grassi G, Borghi C, et al. Determinants of healing among patients with COVID-19: the results of the SARS-RAS study of the Italian Society of Hypertension. J Hypertens. 2020. https:\/\/doi.org\/10.1097\/HJH.0000000000002666.","journal-title":"J Hypertens."},{"key":"439_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13293-020-00304-9","volume":"11","author":"C Gebhard","year":"2020","unstructured":"Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29.","journal-title":"Biol Sex Differ."},{"key":"439_CR9","unstructured":"Sex, gender and COVID-19. Global Health 5050. 2020. https:\/\/globalhealth5050.org\/covid19\/."},{"key":"439_CR10","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/jcm9061862","volume":"9","author":"W Mosleh","year":"2020","unstructured":"Mosleh W, Chen K, Pfau SE, et al. Endothelial dysfunction in patients with COVID-19: its role in thrombosis and adverse outcomes. J Clin Med. 2020;9:1862.","journal-title":"J Clin Med."},{"key":"439_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8917578","volume":"2016","author":"S Bernardi","year":"2016","unstructured":"Bernardi S, Michelli A, Zuolo G, et al. Update on RAAS modulation for the treatment of diabetic cardiovascular disease. J Diabetes Res. 2016;2016:1\u201317.","journal-title":"J Diabetes Res."},{"issue":"5","key":"439_CR12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537\u201340.","journal-title":"Drug Dev Res."},{"key":"439_CR13","volume-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","author":"G Li","year":"2020","unstructured":"Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV), vol. 19. Berlin: Nature Publishing Group; 2020."},{"key":"439_CR14","doi-asserted-by":"crossref","unstructured":"Honardoost M, Aghili R, Khamsch ME. Coronavirus 2019 infection in people with associated comorbidities: case fatality and ACE2 inhibitors treatment concerns. Preprints 2020.","DOI":"10.20944\/preprints202004.0331.v1"},{"issue":"1","key":"439_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/v11010059","volume":"11","author":"Z Song","year":"2019","unstructured":"Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59.","journal-title":"Viruses."},{"key":"439_CR16","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.peptides.2005.01.009","volume":"26","author":"F Gembardt","year":"2005","unstructured":"Gembardt F, Sterner-Kock A, Imboden H, et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides. 2005;26:1270\u20137.","journal-title":"Peptides"},{"key":"439_CR17","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/gut.2004.062398","volume":"54","author":"G Paizis","year":"2005","unstructured":"Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54:1790\u20136.","journal-title":"Gut"},{"issue":"14","key":"439_CR18","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","volume":"100","author":"RAS Santos","year":"2003","unstructured":"Santos RAS, Silva ACS, Maric C, et al. Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci. 2003;100(14):8258\u201363.","journal-title":"Proc Natl Acad Sci."},{"key":"439_CR19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1152\/ajpendo.00490.2012","volume":"304","author":"KH Chhabra","year":"2013","unstructured":"Chhabra KH, Xia H, Pedersen KB, et al. Pancreatic angiotensin-converting enzyme 2 (ACE2) improves glycemia in angiotensin II-infused mice. Am J Physiol Endocrinol Metab. 2013;304:874\u201384.","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"439_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/HCO.0b013e3281532b53","volume":"22","author":"H Hitomi","year":"2007","unstructured":"Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol. 2007;22:311\u20135.","journal-title":"Curr Opin Cardiol"},{"key":"439_CR21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1196\/annals.1293.017","volume":"1011","author":"K Yoshitaka","year":"2004","unstructured":"Yoshitaka K, Hideaki K. Role of oxidative stress in pancreatic \u03b2 -cell dysfunction. Ann NY Acad Sci. 2004;1011:168\u201376.","journal-title":"Ann NY Acad Sci."},{"issue":"6","key":"439_CR22","first-page":"725","volume":"8","author":"MR Hayden","year":"2007","unstructured":"Hayden MR, Karuparthi PR, Habibi J, et al. Ultrastructural Islet study of early fibrosis in the Ren2 Rat model of hypertension emerging role of the Islet pancreatic pericyte-stellate cell. JOP. 2007;8(6):725\u201338.","journal-title":"JOP."},{"key":"439_CR23","first-page":"325","volume":"24","author":"MY Donath","year":"2009","unstructured":"Donath MY, B\u00f6ni-Schnetzler M, Ellingsgaard H, et al. Islet inflammation impairs the pancreatic \u03b2-cell in type 2 diabetes. Am Physiol Soc. 2009;24:325\u201331.","journal-title":"Am Physiol Soc."},{"key":"439_CR24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1152\/ajpendo.1996.271.6.E990","volume":"271","author":"PO Carlsson","year":"1996","unstructured":"Carlsson PO, Andersson A, Jansson L. Pancreatic islet blood flow in normal and obese-hyperglycemic (ob\/ob) mice. Am J Physiol Endocrinol Metab. 1996;271:990\u20135.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"439_CR25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tem.2012.06.003","volume":"23","author":"M Flamment","year":"2012","unstructured":"Flamment M, Hajduch E, Ferre P, et al. New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab. 2012;23:381\u201390.","journal-title":"Trends Endocrinol Metab."},{"issue":"11","key":"439_CR26","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1172\/JCI64583","volume":"122","author":"CN Young","year":"2012","unstructured":"Young CN, Cao X, Guruju MR, Pierce JP, et al. ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. J Clin Invest. 2012;122(11):3960\u20134.","journal-title":"J Clin Invest."},{"key":"439_CR27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1096\/fasebj.27.1_supplement.1154.1","volume":"27","author":"KH Chhabra","year":"2013","unstructured":"Chhabra KH, Pedersen KB, Xia H, et al. Pancreatic ACE2 shedding is associated with impaired glycemia in high fat diet-fed mice. FASEB J. 2013;27:1154.","journal-title":"FASEB J."},{"key":"439_CR28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3727\/096368911X603639","volume":"21","author":"S Negi","year":"2012","unstructured":"Negi S, Park SH, Jetha A, et al. Evidence of endoplasmic reticulum stress mediating cell death in transplanted human islets. Cell Transplant. 2012;21:889\u2013900.","journal-title":"Cell Transplant."},{"key":"439_CR29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.HYP.0000060689.38912.CB","volume":"41","author":"C Tikellis","year":"2003","unstructured":"Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392\u20137.","journal-title":"Hypertension"},{"key":"439_CR30","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/db09-0782","volume":"59","author":"SM Bindom","year":"2010","unstructured":"Bindom SM, Hans CP, Xia H, et al. Angiotensin-I converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes. 2010;59:2540\u20138.","journal-title":"Diabetes"},{"issue":"10","key":"439_CR31","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/db09-0280","volume":"58","author":"M Cardellini","year":"2009","unstructured":"Cardellini M, Menghini R, Martelli E, et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes. 2009;58(10):2396\u2013401.","journal-title":"Diabetes"},{"key":"439_CR32","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"DW Lambert","year":"2005","unstructured":"Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113\u20139.","journal-title":"J Biol Chem."},{"key":"439_CR33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/iub.1190","volume":"65","author":"KH Chhabra","year":"2013","unstructured":"Chhabra KH, Chodavarapu H, Lazartigues E. Angiotensin converting enzyme 2: a new important player in the regulation of glycemia. IUBMB Life. 2013;65:731\u20138.","journal-title":"IUBMB Life"},{"issue":"1","key":"439_CR34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11897-013-0178-0","volume":"11","author":"MAR Chamsi-Pasha","year":"2014","unstructured":"Chamsi-Pasha MAR, Shao Z, et al. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep. 2014;11(1):58\u201363.","journal-title":"Curr Heart Fail Rep."},{"key":"439_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/256294","volume":"2012","author":"C Tikellis","year":"2012","unstructured":"Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012:1\u20138.","journal-title":"Int J Pept."},{"issue":"2","key":"439_CR36","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3892\/mmr.2017.6848","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, He W, Guo L, et al. The ACE2-Ang (1\u20137)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. Mol Med Rep. 2017;16(2):1973\u201381.","journal-title":"Mol Med Rep."},{"issue":"3","key":"439_CR37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ki.2012.127","volume":"82","author":"RC Harris","year":"2012","unstructured":"Harris RC. Podocyte ACE2 protects against diabetic nephropathy. Kidney Int. 2012;82(3):255\u20136.","journal-title":"Kidney Int"},{"issue":"12","key":"439_CR38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1590\/1414-431x20154583","volume":"48","author":"G Foureaux","year":"2015","unstructured":"Foureaux G, Nogueira BS, Coutinho DCO, et al. Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina. Braz J Med Biol Res. 2015;48(12):1109\u201314.","journal-title":"Braz J Med Biol Res."},{"key":"439_CR39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.omtm.2019.06.007","volume":"14","author":"A Verma","year":"2019","unstructured":"Verma A, Xu K, Du T, et al. Expression of human ACE2 in Lactobacillus and beneficial effects in diabetic retinopathy in mice. Mol Ther Methods Clin Dev. 2019;14:161\u201370.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"439_CR40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FJC.0b013e3180986219","volume":"50","author":"MK Raizada","year":"2007","unstructured":"Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007;50:112\u20139.","journal-title":"J Cardiovasc Pharmacol."},{"key":"439_CR41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.mce.2008.09.020","volume":"302","author":"SM Bindom","year":"2009","unstructured":"Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol. 2009;302:193\u2013202.","journal-title":"Mol Cell Endocrinol"},{"key":"439_CR42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.regpep.2012.05.093","volume":"177","author":"TM Murca","year":"2012","unstructured":"Murca TM, Moraes PL, Capuruco CAB, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept. 2012;177:107\u201315.","journal-title":"Regul Pept"},{"key":"439_CR43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/db09-1218","volume":"59","author":"GY Oudit","year":"2010","unstructured":"Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59:529\u201338.","journal-title":"Diabetes"},{"key":"439_CR44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.biocel.2005.08.007","volume":"38","author":"C Tikellis","year":"2006","unstructured":"Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol. 2006;38:737\u201351.","journal-title":"Int J Biochem Cell Biol."},{"key":"439_CR45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2004.02.023","volume":"316","author":"SH Ko","year":"2004","unstructured":"Ko SH, Kwon HS, Kim SR, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun. 2004;316:114\u201322.","journal-title":"Biochem Biophys Res Commun."},{"key":"439_CR46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/diabetes.55.02.06.db05-1022","volume":"55","author":"KY Chu","year":"2006","unstructured":"Chu KY, Lau T, Carlsson PO, et al. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006;55:367\u201374.","journal-title":"Diabetes"},{"key":"439_CR47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/eje.1.02086","volume":"154","author":"R Lupi","year":"2006","unstructured":"Lupi R, Del Guerra S, Bugliani M, et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol. 2006;154:355\u201361.","journal-title":"Eur J Endocrinol."},{"key":"439_CR48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2337\/dc09-1579","volume":"33","author":"AJ Hanley","year":"2010","unstructured":"Hanley AJ, Zinman B, Sheridan P, et al. Effect of Rosiglitazone and Ramipril on -cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care. 2010;33:608\u201313.","journal-title":"Diabetes Care"},{"key":"439_CR49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc06-1745","volume":"30","author":"S Bokhari","year":"2007","unstructured":"Bokhari S, Israelian Z, Schmidt J, et al. Effects of angiotensin II type 1 receptor blockade on beta-cell function in humans. Diabetes Care. 2007;30:181\u2013181.","journal-title":"Diabetes Care"},{"key":"439_CR50","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJM198909283211305","volume":"321","author":"T Pollare","year":"1989","unstructured":"Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868\u201373.","journal-title":"N Engl J Med."},{"key":"439_CR51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10641960802269927","volume":"30","author":"K Suzuki","year":"2008","unstructured":"Suzuki K, Nakagawa O, Aizawa Y. Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens. 2008;30:309\u201314.","journal-title":"Clin Exp Hypertens."},{"issue":"14","key":"439_CR52","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.00998-13","volume":"87","author":"AO Adedeji","year":"2013","unstructured":"Adedeji AO, Severson W, Jonsson C, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013;87(14):8017\u201328.","journal-title":"J Virol"},{"key":"439_CR53","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562\u20139.","journal-title":"Nat Microbiol."},{"key":"439_CR54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, et al. Angiotensin converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450\u20134.","journal-title":"Nature"},{"key":"439_CR55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586\u201390.","journal-title":"Intensive Care Med."},{"key":"439_CR56","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875\u20139.","journal-title":"Nat Med."},{"key":"439_CR57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1152\/ajplung.00009.2008","volume":"295","author":"X Li","year":"2008","unstructured":"Li X, Molina-Molina M, Abdul-Hafez A, et al. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;295:178\u201385.","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"439_CR58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364\u201374.","journal-title":"Sci China Life Sci."},{"key":"439_CR59","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","volume":"39","author":"GY Oudit","year":"2009","unstructured":"Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618\u201325.","journal-title":"Eur J Clin Invest."},{"key":"439_CR60","doi-asserted-by":"crossref","first-page":"m810","DOI":"10.1136\/bmj.m810","volume":"368","author":"J Watkins","year":"2020","unstructured":"Watkins J. Preventing a covid-19 pandemic. BMJ. 2020;368:m810.","journal-title":"BMJ"},{"key":"439_CR61","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation"},{"key":"439_CR62","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1152\/ajpheart.00217.2020","volume":"318","author":"AM South","year":"2020","unstructured":"South AM, Diz D, Chappell MC. COVID-19, ACE2 and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:1084\u201390.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"439_CR63","doi-asserted-by":"crossref","first-page":"104350","DOI":"10.1016\/j.yexmp.2019.104350","volume":"113","author":"R Ye","year":"2019","unstructured":"Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol. 2019;113:104350.","journal-title":"Exp Mol Pathol."},{"key":"439_CR64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","volume":"75","author":"AHJ Danser","year":"2020","unstructured":"Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382\u20135.","journal-title":"Hypertension"},{"key":"439_CR65","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020;382:1653\u20139.","journal-title":"N Engl J Med."},{"issue":"8","key":"439_CR66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"439_CR67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"A Cortegiani","year":"2020","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279\u201383.","journal-title":"J Crit Care"},{"key":"439_CR68","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3389\/fimmu.2020.02132","volume":"11","author":"V Castelli","year":"2020","unstructured":"Castelli V, Cimini A, Claudio F. Cytokine storm in COVID-19: \u201cWhen you come out of the storm, you won\u2019t be the same person who walked in.\u201d Front Immunol. 2020;11:2132.","journal-title":"Front Immunol."},{"issue":"8","key":"439_CR69","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1073\/pnas.0307140101","volume":"101","author":"J Sui","year":"2004","unstructured":"Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. PNAS. 2004;101(8):2536\u201341.","journal-title":"PNAS"},{"key":"439_CR70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234.","journal-title":"Crit Care."},{"key":"439_CR71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40292-020-00380-3","volume":"27","author":"G Laccarino","year":"2020","unstructured":"Laccarino G, Borghi C, Cicero AFG, et al. Renin-Angiotensin System inhibition in cardiovascular patients at the time of COVID-19: much Ado for nothing? A statement of activity from the directors of the board and the scientific directors of the Italian Society of Hypertension. High Blood Press Cardiovasc Prev. 2020;27:105\u20138.","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"439_CR72","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2020.07.002","author":"DL Edmonston","year":"2020","unstructured":"Edmonston DL, South AM, Sparks MA, et al. Coronavirus disease 2019 and hypertension: the role of angiotensin-converting enzyme2 and the renin\u2013angiotensin-system. Adv Chronic Kidney Dis. 2020. https:\/\/doi.org\/10.1053\/j.ackd.2020.07.002.","journal-title":"Adv Chronic Kidney Dis"},{"key":"439_CR73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2020.05.002","volume":"226","author":"RD Lopes","year":"2020","unstructured":"Lopes RD, Macedo AVS, Barros-e-Silva PGM, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus2 (SARS-CoV-2)-The BRACE CORONA Trial. Am Heart J. 2020;226:49\u201359.","journal-title":"Am Heart J."},{"issue":"5","key":"439_CR74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"YY Zheng","year":"2020","unstructured":"Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259\u201360.","journal-title":"Nat Rev Cardiol."},{"issue":"7","key":"439_CR75","doi-asserted-by":"crossref","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","volume":"9","author":"R Sommerstein","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, et al. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9(7):e016509.","journal-title":"J Am Heart Assoc."},{"issue":"7047","key":"439_CR76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112\u20136.","journal-title":"Nature"},{"issue":"12","key":"439_CR77","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671\u201381.","journal-title":"Circ Res."},{"issue":"22","key":"439_CR78","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","volume":"41","author":"C Gao","year":"2020","unstructured":"Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058\u201366.","journal-title":"Eur Heart J."},{"issue":"8","key":"439_CR79","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","volume":"222","author":"KW Lam","year":"2020","unstructured":"Lam KW, Chow KW, Vo J, et al. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis. 2020;222(8):1256\u201364.","journal-title":"J Infect Dis."},{"issue":"1","key":"439_CR80","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757\u201360.","journal-title":"Emerg Microbes Infect."},{"issue":"2","key":"439_CR81","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168\u201377.","journal-title":"JAMA"},{"issue":"25","key":"439_CR82","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of covid-19. New Engl J Med. 2020;382(25):2441\u20138.","journal-title":"New Engl J Med."},{"issue":"2","key":"439_CR83","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/HYPERTENSIONAHA.120.15324","volume":"76","author":"G Iaccarino","year":"2020","unstructured":"Iaccarino G, Grassi G, Borghi C, et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the italian society of hypertension. Hypertension. 2020;76(2):366\u201372.","journal-title":"Hypertension"},{"issue":"10238","key":"439_CR84","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","volume":"395","author":"FJ de Abajo","year":"2020","unstructured":"de Abajo FJ, Rodr\u00edguez-Mart\u00edn S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705\u201314.","journal-title":"Lancet"},{"key":"439_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa624","author":"SY Jung","year":"2020","unstructured":"Jung SY, Choi JC, You SH, et al. Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa624.","journal-title":"Clin Infect Dis."},{"key":"439_CR86","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.31.929042","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Kr\u00fcger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.01.31.929042","journal-title":"bioRxiv"},{"key":"439_CR87","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","volume":"86","author":"M Kawase","year":"2012","unstructured":"Kawase M, Shirato K, van der Hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537\u201345.","journal-title":"J Virol."},{"key":"439_CR88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76\u201384.","journal-title":"Antiviral Res."},{"key":"439_CR89","unstructured":"European Society of Cardiology [Internet]. Sophia Antipolis (France). [cited 2020 Mar 13]. Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. Available from: https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-%A0(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-%A0and-ang."},{"key":"439_CR90","unstructured":"American College of cardiology [Internet]. Washington (DC). [cited 2020 Mar 17]. HFSA\/ACC\/AHA Statement Addresses Concerns Re: using RAAS Antagonists in COVID-19. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19."}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-021-00439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40292-021-00439-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-021-00439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T04:28:50Z","timestamp":1671424130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40292-021-00439-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s40292-021-00439-9","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was not funded by any funding agency.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"First author contributed in conceptual writing and author two contributed in conceptual writing, critical reading and reviewing the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributors"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}